Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection : test negative design study
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: To determine whether time elapsed since the second injection of the Pfizer-BioNTech BNT162b2 mRNA vaccine was significantly associated with the risk of covid-19 infection after vaccination in people who received two vaccine injections.
DESIGN: Test negative design study.
SETTING: Electronic health records of a large state mandated healthcare organisation, Israel.
PARTICIPANTS: Adults aged ≥18 years who had received a reverse transcription polymerase chain reaction (RT-PCR) test between 15 May 2021 and 17 September 2021, at least three weeks after their second vaccine injection, had not received a third vaccine injection, and had no history of covid-19 infection.
MAIN OUTCOME MEASURES: Positive result for the RT-PCR test. Individuals who tested positive for SARS-CoV-2 and controls were matched for week of testing, age category, and demographic group (ultra-orthodox Jews, individuals of Arab ancestry, and the general population). Conditional logistic regression was adjusted for age, sex, socioeconomic status, and comorbid conditions.
RESULTS: 83 057 adults received an RT-PCR test for SARS-CoV-2 during the study period and 9.6% had a positive result. Time elapsed since the vaccine injection was significantly longer in individuals who tested positive (P<0.001). Adjusted odds ratio for infection at time intervals >90 days since vaccination were significantly increased compared with the reference of <90 days: 2.37 (95% confidence interval 1.67 to 3.36) for 90-119 days, 2.66 (1.94 to 3.66) for 120-149 days, 2.82 (2.07 to 3.84) for 150-179 days, and 2.82 (2.07 to 3.85) for ≥180 days (P<0.001 for each 30 day interval).
CONCLUSIONS: In this large population of adults tested for SARS-CoV-2 by RT-PCR after two doses of mRNA BNT162b2 vaccine, a gradual increase in the risk of infection was seen for individuals who received their second vaccine dose after at least 90 days.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:375 |
|---|---|
| Enthalten in: |
BMJ (Clinical research ed.) - 375(2021) vom: 24. Nov., Seite e067873 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Israel, Ariel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 03.12.2021 Date Revised 16.07.2022 published: Electronic UpdateOf: medRxiv. 2021 Aug 05;:. - PMID 34401882 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmj-2021-067873 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333564731 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333564731 | ||
| 003 | DE-627 | ||
| 005 | 20231225221914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmj-2021-067873 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333564731 | ||
| 035 | |a (NLM)34819275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Israel, Ariel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection |b test negative design study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.12.2021 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2021 Aug 05;:. - PMID 34401882 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: To determine whether time elapsed since the second injection of the Pfizer-BioNTech BNT162b2 mRNA vaccine was significantly associated with the risk of covid-19 infection after vaccination in people who received two vaccine injections | ||
| 520 | |a DESIGN: Test negative design study | ||
| 520 | |a SETTING: Electronic health records of a large state mandated healthcare organisation, Israel | ||
| 520 | |a PARTICIPANTS: Adults aged ≥18 years who had received a reverse transcription polymerase chain reaction (RT-PCR) test between 15 May 2021 and 17 September 2021, at least three weeks after their second vaccine injection, had not received a third vaccine injection, and had no history of covid-19 infection | ||
| 520 | |a MAIN OUTCOME MEASURES: Positive result for the RT-PCR test. Individuals who tested positive for SARS-CoV-2 and controls were matched for week of testing, age category, and demographic group (ultra-orthodox Jews, individuals of Arab ancestry, and the general population). Conditional logistic regression was adjusted for age, sex, socioeconomic status, and comorbid conditions | ||
| 520 | |a RESULTS: 83 057 adults received an RT-PCR test for SARS-CoV-2 during the study period and 9.6% had a positive result. Time elapsed since the vaccine injection was significantly longer in individuals who tested positive (P<0.001). Adjusted odds ratio for infection at time intervals >90 days since vaccination were significantly increased compared with the reference of <90 days: 2.37 (95% confidence interval 1.67 to 3.36) for 90-119 days, 2.66 (1.94 to 3.66) for 120-149 days, 2.82 (2.07 to 3.84) for 150-179 days, and 2.82 (2.07 to 3.85) for ≥180 days (P<0.001 for each 30 day interval) | ||
| 520 | |a CONCLUSIONS: In this large population of adults tested for SARS-CoV-2 by RT-PCR after two doses of mRNA BNT162b2 vaccine, a gradual increase in the risk of infection was seen for individuals who received their second vaccine dose after at least 90 days | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Merzon, Eugene |e verfasserin |4 aut | |
| 700 | 1 | |a Schäffer, Alejandro A |e verfasserin |4 aut | |
| 700 | 1 | |a Shenhar, Yotam |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Ilan |e verfasserin |4 aut | |
| 700 | 1 | |a Golan-Cohen, Avivit |e verfasserin |4 aut | |
| 700 | 1 | |a Ruppin, Eytan |e verfasserin |4 aut | |
| 700 | 1 | |a Magen, Eli |e verfasserin |4 aut | |
| 700 | 1 | |a Vinker, Shlomo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ (Clinical research ed.) |d 1988 |g 375(2021) vom: 24. Nov., Seite e067873 |w (DE-627)NLM012612685 |x 1756-1833 |7 nnns |
| 773 | 1 | 8 | |g volume:375 |g year:2021 |g day:24 |g month:11 |g pages:e067873 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmj-2021-067873 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 375 |j 2021 |b 24 |c 11 |h e067873 | ||